Study offers way to predict onset of lung disease in children with cystic fibrosis
Cystic fibrosis (CF) shortens life by making the lungs prone to repeated bacterial infections and associated inflammation. UNC School of...
Cystic fibrosis drug Orkambi 'approved for use among 6-11 year olds'
The pharmaceutical firm making cystic fibrosis drug Orkambi says it has received EU approval to treat children. Manufacturer Vertex says...
Protein structure could unlock new treatments for cystic fibrosis
Cystic fibrosis is a severe hereditary disease of the lung, for which there is currently no cure. The underlying cause of the disease is...
Advances in the Prevention and Treatment of MRSA in Patients with Cystic Fibrosis
Active research and special expertise at Cleveland Clinic’s Adult CF Center Methicillin-resistant Staphylococcus aureus (MRSA) increases...
Galapagos Initiates Phase 1 Trial to Evaluate CF Corrector GLP3221 in Healthy Volunteers
Galapagos has initiated a Phase 1 clinical trial in healthy volunteers to evaluate a new C2 corrector, called GLPG3221, developed for the...
Case Report Provides New Insights on Dosing of Novel Drug for Patients with Cystic Fibrosis
Ceftolozane/tazobactam is safe, effective, and well-tolerated in the treatment of multidrug-resistant Pseudomonas aeruginosa infection...
Europe’s CHMP Gives Its Blessing to Vertex’s Orkambi as CF Therapy for Younger Children
The European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Orkambi...
Help Comes in the Form of Biosensors for Cystic Fibrosis Patients
A new biosensor tool’s been developed by Imperial researchers that lights up when any harmful bacteria is detected in the lung. ...
Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Li
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has doubled the number of scholarships for people living with cystic fibrosis (CF) and...
